Background: New light shed on the cholinergic aspects of vitiligo pathophysiology. It was
found that acetylcholine concentration increased with a significantly reduced expression of
acetylcholinesterase in vitiliginous patches that return to normal up on repigmentation.
Objective: The investigators will undertook this controlled, prospective pilot study to
evaluate the efficacy and safety of botulinum toxin A in patients with localized vitiligo.
Methods: 10 patients with focal or segmental vitiligo will be recruited. For each patient
with focal vitiligo, one or two vitiliginous patches will be treated. The other patches will
be used as control. For each patient with segmental vitiligo, half of the lesion will be
treated. The other half will be used as a control. Botulinum toxin will be injected. The
response will be analyzed at the initial visit, two weeks and at two and six months after
therapy.
Phase:
Phase 4
Details
Lead Sponsor:
King Saud University
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA